Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Staying Put Despite Q2 Disappointment
Tweet Send to a FriendGet Alerts OPTR Hot Sheet
Price: $14.44 --0%
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 7
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 7
Trade OPTR Now!
Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $18.00 (from $19.00).
Aanlyst, Thomas Russo, said, "Sticking with OPTR following disappointing Q2 report. We expect the stock could remain under pressure from the first meaningful Dificid miss, including a down June to end the quarter. Biotech launch stories aren’t known for instilling patience, but we aren’t prepared to view one bad month, with possible contributing factors, as indicative of a fundamental change, particularly when quantitative comments on July suggest a strong bounce-back. We expect a return to better results and wouldn't sell on weakness here."
FY12 EPS estimate cut from (0.96) to (1.11) and FY12 from (0.78) to (1.32)
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $13.66 yesterday, with a 52 week range of $6.81-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Aanlyst, Thomas Russo, said, "Sticking with OPTR following disappointing Q2 report. We expect the stock could remain under pressure from the first meaningful Dificid miss, including a down June to end the quarter. Biotech launch stories aren’t known for instilling patience, but we aren’t prepared to view one bad month, with possible contributing factors, as indicative of a fundamental change, particularly when quantitative comments on July suggest a strong bounce-back. We expect a return to better results and wouldn't sell on weakness here."
FY12 EPS estimate cut from (0.96) to (1.11) and FY12 from (0.78) to (1.32)
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $13.66 yesterday, with a 52 week range of $6.81-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: Global Equities Starts Tesla Motors (TSLA) at Overweight
- UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Robert W Baird
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
